These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 1973185)

  • 1. Effector mechanisms in cyclosporine A-induced syngeneic graft-versus-host disease. Role of CD4+ and CD8+ T lymphocyte subsets.
    Hess AD; Fischer AC; Beschorner WE
    J Immunol; 1990 Jul; 145(2):526-33. PubMed ID: 1973185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Host resistance to cyclosporine induced syngeneic graft-versus-host disease. Requirement for two distinct lymphocyte subsets.
    Fischer AC; Laulis MK; Horwitz L; Beschorner WE; Hess A
    J Immunol; 1989 Aug; 143(3):827-32. PubMed ID: 2526175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the autoreactive T cell repertoire in cyclosporin-induced syngeneic graft-versus-host disease. A highly conserved repertoire mediates autoaggression.
    Fischer AC; Ruvolo PP; Burt R; Horwitz LR; Bright EC; Hess JM; Beschorner WE; Hess AD
    J Immunol; 1995 Apr; 154(8):3713-25. PubMed ID: 7706714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of peripheral autoregulatory mechanisms that prevent development of cyclosporin-induced syngeneic graft-versus-host disease.
    Hess AD; Fischer AC; Horwitz L; Bright EC; Laulis MK
    J Immunol; 1994 Jul; 153(1):400-11. PubMed ID: 8207251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive transfer of murine syngeneic graft-vs.-host disease by CD4+ T cells.
    Bryson JS; Jennings CD; Brandon JA; Perez J; Caywood BE; Kaplan AM
    J Leukoc Biol; 2007 Dec; 82(6):1393-400. PubMed ID: 17726153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional divergence of antigen-specific T-lymphocyte responses in syngeneic graft-versus-host disease.
    Thoburn CJ; Miura Y; Bright EC; Hess AD
    Biol Blood Marrow Transplant; 2004 Sep; 10(9):591-603. PubMed ID: 15319771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome.
    Blazar BR; Taylor PA; Snover DC; Sehgal SN; Vallera DA
    J Immunol; 1993 Nov; 151(10):5726-41. PubMed ID: 8228258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Despite efficient intrathymic negative selection of host-reactive T cells, autoimmune disease may develop in porcine thymus-grafted athymic mice: evidence for failure of regulatory mechanisms suppressing autoimmunity.
    Zhao Y; Rodriguez-Barbosa JI; Shimizu A; Sachs DH; Sykes M
    Transplantation; 2003 Jun; 75(11):1832-40. PubMed ID: 12811242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the pathogenic autoreactive T cells in cyclosporine-induced syngeneic graft-versus-host disease.
    Chen W; Thoburn C; Hess AD
    J Immunol; 1998 Dec; 161(12):7040-6. PubMed ID: 9862741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens.
    Berger M; Wettstein PJ; Korngold R
    Transplantation; 1994 Apr; 57(7):1095-102. PubMed ID: 7909395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unexpected T-cell diversity in syngeneic graft-versus-host disease revealed by interaction with peptide-loaded soluble MHC class II molecules.
    Hess AD; Thoburn CJ; Chen W; Bright AE
    Transplantation; 2003 Apr; 75(8):1361-7. PubMed ID: 12717231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Th1 cytokines and NK cells participate in the development of murine syngeneic graft-versus-host disease.
    Flanagan DL; Jennings CD; Bryson JS
    J Immunol; 1999 Aug; 163(3):1170-7. PubMed ID: 10415011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity.
    Sykes M; Abraham VS; Harty MW; Pearson DA
    J Immunol; 1993 Jan; 150(1):197-205. PubMed ID: 8093257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR; Majewski D; Hanson G
    Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM; Waller EK
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory function for murine intraepithelial lymphocytes. Two subsets of CD3+, T cell receptor-1+ intraepithelial lymphocyte T cells abrogate oral tolerance.
    Fujihashi K; Taguchi T; McGhee JR; Eldridge JH; Bruce MG; Green DR; Singh B; Kiyono H
    J Immunol; 1990 Oct; 145(7):2010-9. PubMed ID: 1975820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease.
    Krenger W; Snyder KM; Byon JC; Falzarano G; Ferrara JL
    J Immunol; 1995 Jul; 155(2):585-93. PubMed ID: 7608537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cells, but not thymic exposure to HLA-B27, are required for the inflammatory disease of HLA-B27 transgenic rats.
    Breban M; Fernández-Sueiro JL; Richardson JA; Hadavand RR; Maika SD; Hammer RE; Taurog JD
    J Immunol; 1996 Jan; 156(2):794-803. PubMed ID: 8543835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoimmune-mediated vasculopathy.
    Chen W; Thoburn CJ; Miura Y; Sommer M; Hruban R; Qian Z; Baldwin W; Hess AD
    Clin Immunol; 2001 Jul; 100(1):57-70. PubMed ID: 11414746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclosporine-induced syngeneic graft-vs-host disease: prevention of autoaggression by treatment with monoclonal antibodies to T lymphocyte cell surface determinants and to MHC class II antigens.
    Hess AD; Horwitz LR; Laulis MK; Fuchs E
    Clin Immunol Immunopathol; 1993 Dec; 69(3):341-50. PubMed ID: 7694818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.